<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945018</url>
  </required_header>
  <id_info>
    <org_study_id>HS-001-01</org_study_id>
    <nct_id>NCT04945018</nct_id>
  </id_info>
  <brief_title>A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)</brief_title>
  <acronym>LAPiS</acronym>
  <official_title>A Phase I/II Study of Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Severe Heart Failure, Secondary to Ischemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heartseed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heartseed Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS&#xD;
      transplanted into severe heart failure patients with underlying ischemic heart disease for 26&#xD;
      weeks after transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, two-group dose-escalation, phase I/II study in 10 severe&#xD;
      heart failure patients (five in the low-dose group and five in the high-dose group) with&#xD;
      underlying ischemic heart disease.&#xD;
&#xD;
      After screening period is completed, subjects undergo HS-001 CS transplantation. After&#xD;
      transplantation, subjects take immunosuppressant and have efficacy/safety assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 19, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>26 weeks post-transplant</time_frame>
    <description>Adverse events and safety in the 26 weeks after HS-001 CS transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction in Cardiac MRI scan &amp; Echocardiography</measure>
    <time_frame>26 weeks and 52 weeks post-transplant</time_frame>
    <description>Left Ventricular Ejection Fraction in the 26 weeks and 52 weeks after HS-001 CS transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial wall motion evaluation in Echocardiography</measure>
    <time_frame>26 weeks and 52 weeks post-transplant</time_frame>
    <description>Myocardial wall motion evaluation (Index of myocardial strain) in the 26 weeks and 52 weeks after HS-001 CS transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial blood flow in SPECT</measure>
    <time_frame>26 weeks and 52 weeks post-transplant</time_frame>
    <description>Myocardial blood flow in the 26 weeks and 52 weeks after HS-001 CS transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial viability in SPECT</measure>
    <time_frame>26 weeks and 52 weeks post-transplant</time_frame>
    <description>Myocardial viability in the 26 weeks and 52 weeks after HS-001 CS transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>26 weeks and 52 weeks post-transplant</time_frame>
    <description>6-minute walk distance in the 26 weeks and 52 weeks after HS-001 CS transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>26 weeks and 52 weeks post-transplant</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire in the 26 weeks and 52 weeks after HS-001 CS transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-level EQ-5D version (EQ-5D-5L)</measure>
    <time_frame>26 weeks and 52 weeks post-transplant</time_frame>
    <description>5-level EQ-5D version (EQ-5D-5L) in the 26 weeks and 52 weeks after HS-001 CS transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>26 weeks and 52 weeks post-transplant</time_frame>
    <description>N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) in the 26 weeks and 52 weeks after HS-001 CS transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>HS-001 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-001 Low dose Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-001 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-001 High dose Administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HS-001 CS</intervention_name>
    <description>Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension</description>
    <arm_group_label>HS-001 High dose</arm_group_label>
    <arm_group_label>HS-001 Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HS-001-D needle, HS-001-D Adaptor</intervention_name>
    <description>Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors</description>
    <arm_group_label>HS-001 High dose</arm_group_label>
    <arm_group_label>HS-001 Low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with resting left ventricular ejection fraction (LVEF) â‰¦40% based on&#xD;
             institutional assessment on either screening cardiac MRI or echocardiographic&#xD;
             assessment&#xD;
&#xD;
          -  New York Heart Association (NYHA) cardiac function classification of grade II or&#xD;
             higher at screening&#xD;
&#xD;
          -  Other Criteria apply, please contact the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients screened less than 1 month after the onset of myocardial infarction&#xD;
&#xD;
          -  Patients with congenital heart disease, or cardiac sarcoidosis&#xD;
&#xD;
          -  Other Criteria apply, please contact the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heartseed Inc.</last_name>
    <phone>0363801068</phone>
    <email>contact@heartseed.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Marianna University Hospital</name>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Medical Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Geriatric Medical Center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Ischemic Heart Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

